share_log

New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men

New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men

發表在美國國家癌症研究所雜誌上的新數據表明,Veracyte的解密前列腺癌基因組分類器可以提高對非裔美國男性侵襲性前列腺癌的識別
Benzinga Real-time News ·  2022/09/22 08:58
Veracyte, Inc. (NASDAQ:VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company's Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data, from the prospective, multi-site VANDAAM Phase 2 clinical study, suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes.
Veracyte,Inc.(納斯達克代碼:VCYT)宣佈,今天發表在《美國國家癌症研究所雜誌》證明該公司的解密前列腺癌基因組分類器可能有助於識別患有早期局部前列腺癌的非裔美國人,他們最有可能患有更具侵襲性的疾病。來自前瞻性、多部位VANDAAM第二階段臨牀研究的數據表明,在非洲裔美國男性中前列腺癌的風險分層方面,基因組測試可能會比單獨的臨牀因素提供強有力的改善,這可能有助於減少前列腺癌結果的差異。
"While African American men have both higher incidence and mortality associated...
Moffitt癌症中心...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論